Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Conditions:   Solid Tumor;   Non-Small Cell Lung Cancer;   Melanoma;   Head and Neck Cancer;   Gastric Cancer;   Renal Cell Carcinoma;   Urothelial Carcinoma
Interventions:   Drug: INBRX-106 – Hexavalent OX40 agonist antibody;   Drug: Pembrolizumab
Sponsors:   Inhibrx, Inc.;   Merck Sharp & Dohme Corp.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 3, 2020 / by / in
Comments